Concentration Pharmaceutical Valuation 
Musings on Markets
OCTOBER 6, 2023
The resulting debate among accountants about how to bring intangibles on to the books has spilled over into valuation practice, and many appraisers and analysts are wrongly, in my view, letting the accounting debate affect how they value companies.
CFO News Room
JANUARY 17, 2023
Consequently, I will concentrate this post on how this crisis is playing out in markets, and the effects it has had, so far, on businesses and investments, and whether these effects are likely to be transient or permanent. I revisited my valuation of the index, with the updated values: Spreadsheet to value the S&P 500.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Musings on Markets
MARCH 19, 2022
Consequently, I will concentrate this post on how this crisis is playing out in markets, and the effects it has had, so far, on businesses and investments, and whether these effects are likely to be transient or permanent. In the last few days, every company on the list has dipped in price by enough to be at least fairly valued or even cheap.
Barry Ritholtz
DECEMBER 12, 2023
Low price stock has historically had some very large concentrated positions. And those concentrated positions happen because they have high conviction that they’re in that group where it’s not stupid to think about where earnings will be 10 years out. This is what’s wrong with concentrating in the wrong stocks.
Barry Ritholtz
DECEMBER 14, 2022
Because going back to our thematic investing, our portfolio is 80 percent concentrated in warehouses, rental housing, lab office space and hospitality asset. Like, if you think about — when I was growing up, all of the big pharmaceutical companies had these corporate campuses that were highly securitized, deep in suburbs.
Expert insights. Personalized for you.
106 
Let's personalize your content